Preferences help
enabled [disable] Abstract
Number of results
2012 | 39 | 1 | 85-136
Article title

Klinicznie nieczynne hormonalnie guzy przysadki

Title variants
NFPAs-non-functioning pituitary adenomas
Languages of publication
The significant progress made in recent years, especially in the field of imaging techniques and immunohistochemistry, enables an earlier diagnosis and the treatment of clinically non-functioning pituitary adenomas (NFPAs). In spite of this, these tumours still remain an important medical issue for a large number of specialities. The aim of this article is to provide an overview of the etiopathogenesis, diagnosis and treatment of clinically non-functioning pituitary adenomas with special reference to the development of highly advanced methods in surgery as well as radiotherapy and, especially, in pharmacotherapy.
Istotny postęp, jaki dokonał się w ostatnich latach, zwłaszcza w zakresie rozwoju diagnostyki obrazowej i badań immunohistochemicznych, umożliwia wcześniejsze rozpoznawanie, a następnie leczenie nieczynnych hormonalnie gruczolaków przysadki (NFPAs). Mimo to guzy te dalej pozostają istotnym problemem klinicznym dla lekarzy wielu specjalności. Celem pracy jest szczegółowe przedstawienie poglądów na temat etiopatogenezy, obrazu klinicznego, diagnostyki i metod leczenia klinicznie nieczynnych hormonalnie gruczolaków przysadki ze szczególnym uwzględnieniem postępów w technikach chirurgicznych oraz rozszerzających się możliwości radioterapii, a szczególnie farmakoterapii.
Physical description
  • Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1981; 62: 1011-1019.
  • McComb DJ, Ryan N, Horvath E, Kovacs K. Subclinical adenomas of the human pituitary. New light of the old problems. Arch Pathol Lab Med 1983; 107: 488 491.
  • Fainstein DP, Guitelman M, Artese R, Fiszlejder L, Chevin A, Vitale NM i wsp. Retrospective multicentric study of pituitary incidentalomas. Pituitary 2004; 7: 145-148.
  • Sanno N, Oyama K, Tahara S, Teramoto A, Kato Y. A survey of pituitary incidentaloma in Japan. Eur J Endocrinol 2003; 149: 123-127.
  • Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirova MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91: 4769-4775.
  • Katznelson L, Alexander JM, Klibanski A. Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1993; 76: 1089-1094.
  • Kovacs K, Scheithauer BW, Horvath E, Lloyd RV. The World Health Organisation classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 1996; 78: 502-510.
  • Ferrante E, Ferraroni M, Castrignano T, Menticatti L, Anagni M, Reimondo G I wsp. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumours. Eur Jf Endocrinol 2006; 155: 823 829.
  • Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary Tumor Registry: A Novel Clinical Resource. J Clin Endocrinol Metab 2000; 85: 168-174.
  • Cury ML, Fernandes JC, Machado HR, Elias LL, Moreira AC, Castro M. Non functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. Arq Bras Endocrinol Metab 2009; 53: 31-39.
  • Pickett CA. Diagnosis and management of pituitary tumors: recent advances. Prim Care 2003; 30: 765-789.
  • Sievers C, Ising M, Pfister H, Dimopoulou C, Schneider HJ, Roemmler J i wsp. Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls. Eur J Endocrinol 2009; 160: 367-373.
  • Greenman Y, Stern N. Non-functioning pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2009; 23: 625-638.
  • Karbonits M, Carlsen E. Recent clinical and pathophysiological advances in non functioning pituitary adenomas. Horm Res 2009; 71: 123-130.
  • Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
  • Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Artz E
  • Komorowski J, Jankiewicz J, Stępień H. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) in peripheral blood as markers of pituitary tumours. Cytobios 2000; 101: 151-159.
  • Peyster RG, Adler LP, Viscarello RR, Hoover ED, Skarzynski J. CT of the normal pituitary gland. Neuroradiology. 1986; 28:161-165.
  • Nammour GM, Ybarra J, Naheedy MH, Romeo JH, Aron DC. Incidental pituitary macroadenoma: a population- based study. AmJ Med Sci 1997; 314: 287-291.
  • Yue NC, Longstreth WT Jr, Elster AD, Jungreis CA, O'Leary DH, Poirier VC. Clinically serious abnormalities found incidentally at MR imaging of the brain; data from the Cardiovascular Health Study. Radiology 1997; 202: 41-46.
  • Freda PU, Post KD. Differential diagnosis of sellar masses. Endocrine Metab Clin North Am 1999; 28: 81-117.
  • Pituitary Incidentaloma. An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 894-904.
  • Buurman H, Saeger W. Subclinical adenomas in post-mortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol 2006; 154: 753 758.
  • Feldkamp J, Santen R, Harms E, Aulich A, Modder U, Scherbaum WA. Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas - results of a prospective study. Clin Endocrinol (Oxf) 1999; 51:109-113.
  • Reincke M, Allolio B, Saeger W, Menzel J, Winkelmann W. The 'incidentaloma' of the pituitary gland. Is neurosurgery required? JAMA 1990; 263: 2772-2776.
  • Arita K, Tominaga A, Sugiyama K, Eguchi K, Iida K, Sumida M i wsp. Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J. Neurosurg., 2006; 104: 884-891.
  • Dekkers OM, Pereira M, Romijn JA. Treatment and Follow-Up of Clinically Non-functioning Pituitary Macroadenomas. J Clin Endocrinol Metab 2008; 93: 3717-3726.
  • Kunert-Radek J. Incydentaloma przysadki. Borgis - Postępy Nauk Medycznych 2007; 10: 399-402.
  • Freda PU, Wardlaw SL, Post KD. Unusual causes of sellar/parasellar masses in large transsphenoidal surgical series. J Clin Endocrinol Metab 1996; 81: 3455 3459.
  • Soto-Ares G, Cortet-Rudelli C, Assaker R, Boulinguez A, Dubest C, Dewailly D i wsp. MRI protocol technique in the optimal therapeutic strategy of non functioning pituitary adenomas. Eur J Endocrinol 2002; 146: 179-186.
  • Ironide JW. Best practice No 172: pituitary gland pathology. J Clin Pathol 2003; 56: 561-568
  • Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Llyood RV, Meyer FB i wsp. Clinically silent corticotroph tumours of the pituitary gland. Neurosurgery 2000; 47: 723-729.
  • Dekkers OM, Pereira AM, Roelfsema F, Voormolen JH, Neelis KJ, Schroijen MA. Observation alone after transsphenoidal surgery for non functioning pituitary macroadenoma. J Clin Endocrinol Metab 2006; 91: 1796-1801.
  • Jane JA, Laws ER. The management of non-functioning pituitary adenomas. Neurol India 2003;51:461-465.
  • Freda PU, Wardlaw SL. Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 1999; 84: 3859-3866.
  • Wagner-Rother M, Hoven S, Kristof RA, Bliesener N, Stoffel-Wichers B. Non functioning pituitary adenomas: endocrinological and clinical outcome. Exp Clin Endocrinol Diabetes 2004; 112: 323-327.
  • Alameda C, Lucas T, Pineda E, Brito M, Uria JG, Magallon R i wsp. Experience in management of 51 non-functioning pituitary adenomas: indications for post operative radiotherapy. J Endocrinol Invest 2005; 28: 18-22.
  • Nomikos P, Ladar C, Fahlbusch R, Buchfelder M. Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas – a study on 721 patients. Acta Neurochir (Wien) [Erratum (2004) 146: 433] 2004; 146: 27-35.
  • Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med 2003; 349: 2035 2041.
  • Liuzzi A, Tassi V, Pirro MT, Zingrillo M, Ghiggi MR, Chiodini I i wsp. Nonfunctioning adenomas of the pituitary. Metabolism 1996; 45: 80-82.
  • Cardoso ER, Peterson EW. Pituitary apoplexy: a review. Neurosurgery 1984; 14: 363-373.
  • Nielsen EH, Lindholm J, Bjerre P, Christiansen JS, Hagen C, Juul S i wsp. Frequent occurrence of pituitary apoplexy in patients with nonfunctioning pituitary adenoma. Clin Endocrinol (Oxf) 2006; 64: 319-322.
  • Hald JK, Eldevik OP, Skalpe IO. Craniopharyngioma identification by CT and MRI imaging at 1,5 T. Acta Radiol 1995; 36: 142-147.
  • Tsuda M, Takahashi S, Higano S, Kurihara N, Ikeda H, Sakamoto K. CT and MR imaging of craniopharyngioma. Eur Radiol 1997; 7: 464-469.
  • Elster AD. Modern imaging of pituitary. Radiology 1993; 187: 1-14.
  • Naidich MJ, Russell EJ. Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am 1999; 28: 45-79.
  • Rand T, Lippitz P, Kink E, Huber H, Schneider B, Imhof H. Evaluation of pituitary microadenomas with dynamic MR imaging. Eur J Radiol 2002; 41: 131-135.
  • Bulski T. Diagnostyka obrazowa patologii okolicy siodła tureckiego i podwzgórza. CMKP Warszawa.
  • Szczeklik A. Choroby wewnętrzne. Kraków, Medycyna Praktyczna 2005.
  • Plockinger U, Bader M, Hopfenmüller W, Saeger W, Quabbe HJ. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to octreotide therapy and do not correlate with tumor histology. Eur J Endocrinol 1997; 136: 369-376.
  • Acosta-Gomez MJ, Muros MA, Llamas-Elvira JM, Ramirez A, Ortega S, Sabatel G i wsp. The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours. The British Journal of Endocrinology 2005; 78: 110-115.
  • Lauriero F, Pierangeli E, Rubini G, Resta M, D'Addabbo A. Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post surgical residues. Nucl Med Commun 1998; 19: 1127-1134.
  • Colao A, Lastoria S, Ferone D, Varella P, Marzullo P, Pivonello R i wsp. Pituitary uptake of In-111-DTPA-D-Phe-octreotide in the normal pituitary and in pituitary adenomas. J Endocrinol Invest 1999; 22: 176-183.
  • Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrant G, Klung N i wsp. Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 1998; 25: 675–686.
  • Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Llyod RV i wsp. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol 2009; 71: 92-99.
  • Mahta A, Haghpanah V, Lashkari A, Heshmat R, Larijani B, Tavagar SM. Non functioning pituitary adenoma: immunohistochemical analysis of 85 cases. Folia Neuropathol 2007; 45: 72-77.
  • Arafah BM, Nasrallah M.P. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 2001; 8: 287-305.
  • Pawlikowski M, Pisarek H, Kunert-Radek J, Radek A. Immunohistochemical detection of somatostatin receptor subtypes in 'clinically nonfunctioning' pituitary adenomas. Endocr Pathol 2003; 14: 231-238.
  • Pawlikowski M, Kunert-Radek J, Radek M. Plurihormonality of pituitary adenomas in light of immunohistochemical studies. Endokrynol Pol 2010; 61: 63 66.
  • Pawlikowski M, Kunert-Radek J, Radek A. Gonadotropinoma - a frequent subtype of the pituitary adenoma. Endokrynol Pol 2000; 51: 77-81.
  • Pawlikowski M, Kuta J, Fuss-Chmielewska J, Winczyk K. 'Silent' somato-tropinoma. Endokrynol Pol 2012; 63: 88-91.
  • Bradley KJ, Waas JA, Turner HE. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol (Oxf) 2003; 58: 59-64.
  • Pizzaro CB, Oliveira MC, Coutinho LB, Ferreira NP. Measurement of Ki-67 antigen in 159 pituitary adenomas using MIB-1 monoclonal antibody. Braz J Med Biol Res 2004; 37: 235-243.
  • Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F i wsp. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 2000; 47: 1313-1318.
  • Hentschel SJ, McCutcheon E, Moore W, Durity FA. P53 and MIB-1 immunohistochemistry as predictors of the clinical behaviour of non-functioning pituitary adenomas. Can J Neurol Sci 2003; 30: 215-219.
  • Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T. The correlation of Ki-67 staining indices wih tumour doubling times in regrowing non functioning pituitary adenomas. Acta Neurochir (Wien) 1996; 138: 1449 1455.
  • Abe T, Sanno N, Osamura YR, Matsumoto K. Proliferative potential in pituitary adenomas: measurement by monoclonal antibody MIB-1. Acta Neurochir (Wien) 1997; 139: 613-618.
  • Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G. Ki 67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol 1999; 52: 107 111.
  • Pawlikowski M, Gruszka A, Kurnatowska I i wsp. Proliferating cell nuclear antigen (PCNA) expression in pituitary adenomas: relationship to the endocrine phenotype of adenoma. Folia Histochem Cytobiol 2006; 44: 37-41.
  • Chaidarun SS, Eggo MC, Sheppard MC, Stewart PM. Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology 1994; 135: 2012 2021.
  • Pawlikowski M. Występowanie receptorów somatostatynowych w ludzkich nowotworach w świetle badań ex vivo-in vitro. Endokrynol Pol 2006; 3: 238-243.
  • Zawada N, Kunert-Radek J. Somatostatin analogues in the treatment of clinically non-functioning pituitary adenomas. Does pharmacotherapy meet expectations?, X Intercontinental Congress of Young Medical Scientists, maj 2010r., Poznań.
  • Kunert-Radek J, Zawada N, Pisarek H, Górska-Chrząstek M, Pawlikowski M. Rola analogów somatostatyny w leczeniu nieczynnych hormonalnie gruczolaków przysadki. III Zjazd Polskiego Towarzystwa Neuroendokrynologicznego, 25 26 listopada 2010r., Kraków.
  • Kunert-Radek J, Pawlikowski M, Pisarek H, Górska-Chrząstek M, Zawada N, Radek M. Detection of somatostatin receptors in aggressive non-functioning pituitary adenomas and effects of somatostatin analogs therapy in these tumors. 15th International&14th European Congress of Endocrinology (ICE/ECE 2012), maj 2012r., Florencja.
  • Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 1998; 78: 189-225.
  • Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl E, Muller A, Lange M i wsp. Heterogenous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1998; 83: 1368-1375.
  • Pivonello R, Matrone C, Filipella M, Cavallo LM, Di Somma C, Cappabianca P i wsp. Dopamine receptor expression and function of clinically nonfunctioning pituitary tumours: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 2004; 89: 1674-1683.
  • Florio T, Barbieri F, Spaziante R, Zona G, Hofland L, van Koetsveld P i wsp. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocrine-Related Cancer 2008; 15: 583-596.
  • Gruszka A, Culler MD, Melmed S. Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro. Mol Cell Endocrinol 2012; 362: 104-109.
  • Gruszka A, Kunert-Radek J, Radek A, Pisarek H, Taylor J, Dong JZ i wsp. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the clinically non-functioning pituitary adenomas in vitro. Life Sciences 2006; 78: 689-693.
  • Reubi JC, Maurer R, von Werder K, Torhorst J, Klijn JG, Lamberts SW. Somatostatin receptors in human endocrine tumors. Cancer Res 1987; 47: 551 558.
  • Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-198.
  • Hofland LJ, Lamberts SW. Somatostatin receptor subtype expression in human tumours. Ann Oncol 2001; 12: 31-36.
  • van der Hoek J, Lamberts SW, Hofland LJ. Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol 2007; 156: 45-51.
  • Nielsen S, Mellemkjaer S, Rasmussen LM, Ledet T, Olsen N, Bojsen-Moller M i wsp. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo. J Endocrinol Invest 2001; 24: 430-437.
  • Pisarek H, Pawlikowski M, Kunert-Radek J, Radek M. Expression of somatostatin receptor subtypes in human pituitary adenomas – immunohisto-chemical studies. Endokrynol Pol 2009; 60: 240-251.
  • Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, van Waaijers PM i wsp. The multiligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005; 152: 645-654.
  • Saveanu A, Morange-Ramos I, Gunz G, Dufour H, Enjalbert A, Jaquet P. A lutinizing hormone-, alpha-subunit- and prolactin- secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies. Eur Journal Endocrinol 2001; 145: 35-41.
  • Dekkers OM, Hammer S, de Keizer RJ, Roelfsema F, Schutte PJ, Smit JW i wsp. The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol 2007; 156: 217-224.
  • Igarashi T, Saeki N, Yamaura A. Long-term magnetic resonance imaging follow up of asymptomatic sellar tumours - their natural history and surgical indications. Neurol Med Chir (Tokyo) 1999; 39: 592-598.
  • Nishizawa S, Ohta S, Yokoyama T, Uemura K. Therapeutic strategy for incidentally found pituitary tumours (pituitary incidentalomas). Neurosurgery 1998; 43: 1344-1348.
  • Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S i wsp. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf) 2007; 67: 938-943.
  • Dekkers O.M. Nonfunctioning Pituitary Macroadenomas. Treatment and long term follow-up. 2006, Doctoral thesis, Leiden University.
  • Nayak PK, Rao KM. Pituitary apoplexy following open cholecystectomy. Pan Arab Journal of Neurosurgery 2010; 14: 119-121.
  • Kim JP, Park BJ, Kim, Lim YJ. Pituitary Apoplexy due to Pituitary Adenoma Infarction. J Korean Neurosurg Soc 2008; 43; 216-249.
  • Liberale G, Bruninx GB, Dubois E, Vandueren E, Verhelst G. Pituitary apoplexy after aortic abdominal aneurysm surgery: a case report. Acta Chir Belg 2006; 106: 77-80.
  • Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CBT, Wass JAH. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol 1999; 51: 181-188.
  • Elsasser Imboden PN, De Tribolet N, Lobrinus A, Gaillard RC, Portman L, Pralong F i wsp. Apoplexy in pituitary macroadenoma: eight patients presenting in 12 months. Medicine (Baltimore) 2005; 84: 188-196.
  • Jaffe CA. Clinically non-functioning pituitary adenoma. Pituitary 2006; 9: 317 321.
  • Chandler WF, Barkan AL. Treatment of pituitary tumours: a surgical perspective. Endocrinol Metab Clin North Am 2008; 37: 51-66.
  • Colao A, Cerbone G, Cappabianca P, Ferone D, Alfieri A, Di Salle F i wsp. Effect of surgery and radiotherapy in visual and endocrine function of nonfunctioning pituitary adenomas. J Endocrinol Invest 1998; 21: 284-290.
  • Emmanuel I. Symposium on pituitary tumours: historical aspects of radiotherapy, present treatment technique, and results. Clinical Radiology 1966; 17: 154-160.
  • Ray R, Patterson R. Surgical experience with chromophobe adenomas of the pituitary gland. Journal Neurosurg 1971; 34: 726-729.
  • Sheline G. Treatment of nonfunctioning adenomas of the pituitary. American Journal of Roentgenology 1974; 120: 553-561.
  • Park P, Chandler WF, Barkan AL, Orrego JJ, Cowan JA, Griffith KA, Tsien C. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 2004; 55: 100-106.
  • Greenman Y, Quaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of quiescence and regrowth. Clin Endocrinol (Oxf) 2003; 58: 763-769.
  • Gittoes NJ, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN i wsp. Radiotherapy for non-functioning pituitary tumours. Clin Endocrinol 1998; 48: 331-337.
  • Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C i wsp. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 2010; 163: 193-200.
  • Honegger J, Zimmermann S, Psaras T, Petrick M, Mittelbronn M, Ernemann U I wsp. Growth modelling on non-functioning pituitary adenomas in patients referred for surgery. Eur J Endocrinol 2008; 158: 287-294.
  • Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age and MIB-1 index. J Neurosurg 2003; 98: 359 365.
  • Dubois S, Guyetant S, Menei P, Rodien P, Illouz F, Vielle B i wsp. Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 2007; 157: 141-147.
  • Scheithauer BW, Gaffey TA, Llyod RV, Sebo TJ, Kovacs KT, Horvath E i wsp. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 2006; 59: 341-353.
  • Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JA, Harris AL. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. Br J Cancer 2000; 82: 1441-1445.
  • Jakobsson KE, Petruson B, Lindblom B. Dynamics of visual field improvement following chiasmal decompression. Quantitative pre- and postoperative observations. Acta Ophthalmol Scand 2002; 80: 512-516.
  • Kerrison JB, Lynn MJ, Baer CA, Newman SA, Biousse V, Newman NJ. Stages of improvement in visual fields after pituitary tumor resection. Am J Ophthalmol 2000; 130: 813-820.
  • Gnanalingham KK, Bhattacharjee S, Pennington R, Ng J, Mendoza N. The time course of visual field recovery following transphenoidal surgery for pituitary adenomas: predictive factors for good outcome. J Neurol Neurosurg Psychiatry 2005; 76: 415-419.
  • Cohen AR, Cooper PR, Kupersmith MJ, Flamm ES, Ransohoff J. Visual recovery after transsphenoidal removal of pituitary adenomas. Neurosurgery 1985; 17: 446-452.
  • Aron DC, Howlett TA. Pituitary incidentalomas. Endocrinol Metab Clin North Am 2000; 29: 205-221.
  • van der Bergh AC, van der BG, Schoorl MA, Sluiter WJ, van der Vliet AM, Hoving EW i wsp. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys 2007; 67: 863-869.
  • Fluckiger E, Wagner HR. 2-Br-alpha-ergocryptin:beinflussung von fertilitat and laktation bei der ratte. Experientia 1968; 24: 1130-1131.
  • de Herder WW, Reijs AEM, Kwekkeboom DJ, Hofland LJ, Nobels FRE, Oei HY i wsp. In vivo imaging of pituitary tumours using a radiolabeled dopamine D2 receptor radioligand. Clin Endocrinol (Oxf) 1996; 45: 755-767.
  • Kwekkeboom DJ, Hofland LJ, Van Koetsveld PM, Singh R, Van den Berge JH, Lamberts SWJ. Bromocriptine increasingly suppresses the in vitro gonadotropin and ƒalfa-subunit release from pituitary adenomas during long term culture. J Endocrinol Metab 1990; 71: 718-725.
  • Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13: 220-240.
  • Wollesen F, Adersen T, Karle A. Size reduction of extracellar pituitary tumors during bromocriptine treatment. Ann Intern Med 1982; 96: 281-286.
  • Pickett CA. Update on the medical management of pituitary adenomas. Currm Neurol Neurosci Rep 2005; 5: 178-185.
  • Kwekkeboom DJ, Lamberts SW. Long-term treatment with the dopamine agonist CV 205-502 of patients with clinically non-functioning, gonadotroph, or ɑ subunit secreting pituitary adenoma. Clin Endocrinol 1992; 36: 171-176.
  • Ivan G, Szigeti-Csucs N, Olah M, Nagy GM, Goth MI. Treatment of pituitary tumors: dopamine agonists. Endocrine 2005; 28: 101-110.
  • Lohmann T, Trantakis C, Biesold M, Prothmann S, Guenzel S, Schober R i wsp. Minor tumor shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary 2001; 4: 173-178.
  • Nobels FR, de Herder WW, van der Brink WM, Kwekkeboom DJ, Hofland LJ, Zuyderwijk J i wsp. Long-term treatment with the dopamine agonist quinagolide of patients with clinically non- functioning pituitary adenoma. Eur J Endocrinol 2000; 143: 615-621.
  • Shomali ME, Katznelson L. Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas. Pituitary 2002; 5: 89-98.
  • Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S. Medical therapy for clinically non-functioning pituitary adenomas. Endocrine-Related Cancer 2008; 15: 905-915.
  • Greenman Y. Dopaminergic treatment of nonfunctioning pituitary adenomas. Nature Clinical Practice. Endocrinology&Metabolism 2007; 3:554-555.
  • Greenman Y, Tordjman K, Osher E i wsp. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol (Oxf) 2005; 63: 39-44.
  • Podlewski JK, Chwalibogowska-Podlewska A, Adamowicz R. Leki współczesnej terapii. Split Trading, Warszawa, 2005.
  • Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for the Parkinson's disease. N Engl J Med 2007; 356: 39-46.
  • Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P. SMS 201 995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Science 1982; 31: 1133-1140.
  • Pawlikowski M. Farmakologiczne leczenie guzów przysadki - historia, stan obecny, przyszłość. Endokrynol Pol 2004; 55: 458-462.
  • Warnet A, Timsit J, Chanson P, Guillausseau PJ, Zamfirescu F, Harris AG i wsp. The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas. J Neurosurg 1989; 71: 687-690.
  • De Bruin TWA, Kwekkeboom DJ, van't Verlaat JW, Reubi JC, Kreening EP, Lamberts SW. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 1992; 75: 1310-1317.
  • Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G i wsp. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas. Q J Nucl Med 1995; 39: 90-93.
  • Duet M, Mundler O, Ajzenberg C, Berolatti B, Chedin P, Durantesu L i wsp. Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index. Eur J Nucl Med 1994; 21: 647-650.
  • Kunert-Radek J, Zawada NB, Pisarek H, Górska-Chrząstek M, Pawlikowski M. Analogi somatostatyny jako alternatywa dla leczenia chirurgicznego u chorych z nawracającymi klinicznie nieczynnymi gruczolakami przysadki. Folia Medica Lodziensia 2012; 39: 131-145.
  • Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptors subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004; 80: 47-50.
  • Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatostatin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146: 707-716.
  • Adams RL, Adams IP, Lindow SW, Atkin SL. Inhibition of endothelial proliferation by the somatostatin analogue pasireotide. Clin Endocrinol 2004; 61: 431-436.
  • Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio M, Bondanelli M i wsp. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocrine Related Cancer 2007; 14: 91-102.
  • Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R i wsp. Somatostatin receptor subtype 1 selective activation in human growth hormone - and prolactin secreting pituitary adenomas: effects of viability. growth hormone and prolactin secretion. J Clin Endocrinol Metabol 2003; 88: 2797-2802.
  • Andersen M, Bjerre P, Schroder HD, Edal A, Hoilund-Carlsen PF, Pedersen PH I wsp. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non functioning pituitary adenomas. Clin Endocrinol 2001; 54: 23-30.
  • Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Teti C i wsp. The clinical molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. Journal of Molecular Endocrinology 2009; 42:361 370.
  • Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T i wsp. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 2008; 93: 1412-1417.
  • Saveanu A, Jaquet P, Brue T, Barlier A. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Mol Cell Endocrinol 2008; 286: 206-213.
  • Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors of dopamine and somatostatin: formation of heterooligomers with enhanced functional activity. Science 2000; 288: 154-157.
  • Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J i wsp. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Euro J Endocrinol 2005; 153: 135-141.
  • Gruszka A, Kunert-Radek J, Radek A. The effect of selective SST1, SST2, SST5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the 'clinically non-functioning' pituitary adenomas in vitro. Life Science 2006; 78: 689-693.
  • Gruszka A, Kunert-Radek J, Radek A, Pisarek H, Culler MD, Pawlikowski M. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists and a somatostatin dopamine chimera on the "clinically non-functioning" pituitary adenomas in vitro, 11th Meeting of the European Neuroendocrine Association, Sorrento-Napoli (Italy), April 24-27, 2004, abstract P14.280.
  • Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W. Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 1980; 98: 617-638.
  • Snyder PJ. Clinically nonfunctioning pituitary adenomas. Endocrinol Metab Clin N Am1993; 22: 163-175.
  • McCord MW, Buatti JM, Fennell EM, Mendenhall WM, Marcus RB, Rhoton AL i wsp. Radiotherapy for pituitary adenoma: long-term outcome and sequelae. Int J Radiat Oncol Biol Phys 1997; 39: 437-444.
  • Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med 1989; 70: 145-160.
  • Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but non serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89: 1613-1617.
  • Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hipopituitarism. Clin Endocrinol 1997; 46: 75-81.
  • Gittoes NJ. Radiotherapy for non-functioning pituitary tumours - when and under what circumstances? Pituitary 2003; 6: 103-108.
  • Tachibana O, Yamaguchi N, Yamashima T, Yamashita J. Radiation necrosis of the optic chiasm, optic tract, hypothalamus, and upper pons after radiotherapy for pituitary adenoma, detected by gadolinium-enhanced. T1-weighted magnetic resonance imaging: case report. Neurosurgery 1990; 27: 640-643.
  • Kline LB, Kim JY, Ceballos R. Radiation optic chiasm neuropathy. Ophthalmology 1985; 92: 1118-1126.
  • Boelaert K, Gittoes NJ. Radiotherapy for non-functioning pituitary adenomas. Eur J Endocrinol 2001; 144: 569-575.
  • Osuch-Wójciekiewicz E, Bruzgelewicz A. Powikłania po radioterapii nowotworów głowy i szyi. Otolaryngologia 2010; 9: 1-6.
  • Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005; 90: 800-804.
  • Devisetty K, Chen LF, Chmura SJ. Envolving use of radiotherapy and radiosurgery in the treatment of pituitary adenomas. Expert Rev. Anticancer Ther 2006; 6: 93-99.
  • Izawa M, Hayashi M, Nakaya K, Satoh H, Ochiai T, Hori T i wsp. Gamma knife radiosurgery for pituitary adenomas. J Neurosurg 2000; 93: 19-22.
  • Jackson IMD, Noren G. Role of gamma knife therapy in the management of pituitary tumors. Endocrinol Metab Clin N Am 1999; 28: 133-142.
  • Pan L, Zhang N, Wang E i wsp. Pituitary adenomas: the effect of gamma knife radiosurgery on tumor growth and endocrinopathies. Stereotact Funct Neurosurg 1998; 70: S119-S126.
  • Shin M, Kurita H, Sasaki T, Tago M, Morita A, Ueki K i wsp. Stereotactic radiosurgery for pituitary adenoma invading the cavernous sinus. J Neurosurg 2000; 93: 2-5.
  • Sheehan J, Kondziolka D, Flickinger J, Lunsford D. Radiotherapy for nonfunctioning pituitary adenoma. Neurosurg Focus 2003; 14: 1-6.
  • Mokry M, Ramschak-Schwarzer S, Simbrunner J, Ganz JC, Pend G. A six year experience with postoperative radiosurgical management of pituitary adenomas. Stereotact Funct Neurosurg 1999; 72: S88-S100.
  • Hoybye C, Rahn T. Adjuvant Gamma Knife radiosurgery in non-functioning pituitary adenomas; low risk of long-term complications in selected patients. Pituitary 2009; 12: 211-216.
  • Jackson IMD, Noren G. Gamma knife radiosurgery for pituitary tumours. Clin Endocrinol Metab 1999; 13: 461-469.
  • Pollock BE, Cochran J, Natt N, Brown PD, Erickson D, Link MJ i wsp. Gamma Knife radiosurgery for patients with non-functioning pituitary adenomas: results from a 15 years experience. Int J Radiat Oncol Biol Phys 2008; 70: 1325-1329.
  • Johnson MD, Woodburn CJ, Vance ML. Quality of life in patients with pituitary adenoma. Pituitary 2003; 6:81-87.
  • Tiemensma J, Kaptein A, Pereira A, Smit J, Romijn J, Biermasz N. Coping Strategies in Patients after Treatment for Functioning or Nonfunctioning Pituitary Adenomas. J Clin Endocrinol Metab 2011; 96: 964-971.
  • Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW i wsp. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 2004; 89: 5369-5376.
  • van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW i wsp. Quality of life in patients after long-term biochemical cure of growth hormone excess. J Clin Endocrinol Metab 2005; 90: 3279-3286.
  • Page RC, Hammersley MS, Burke CW, Wass JA. An account of the quality of life of patients after treatment for nonfunctioning pituitary tumours. Clin Endocrinol (Oxf) 1997; 46: 401-406.
  • Baird A, Sullivan T, Zafar S, Rock J. Quality of life in patients with pituitary tumors: a preliminary study. Qual Manag Health Care 2003; 12: 97-105.
  • Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM i wsp. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQol). Clin Endocrinol (Oxf) 2005; 63: 103-110.
  • Weitzner MA. Neuropsychiatry and pituitary disease: an overview. Psychiatry and Psychosomatics 1998; 67: 125-132.
  • Zgliczyński W. Postępy w rozpoznawaniu i leczeniu choroby Cushinga. Borgis - Postępy Nauk Medycznych 2008, 2: 69-74.
  • Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 2006; 367: 1605-1617.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.